Immuno-oncology company Biosyngen opens new cell therapy GMP facility in Singapore
- Written by Reporters
New state-of-the-art facility to develop immunotherapy assets to address unmet needs in cancer treatment
SINGAPORE - Media OutReach - 28 June 2023 – Biosyngen, an immuno-oncology company with technology targeting the unmet medical needs in solid tumour and lymphoma treatment, today announced the official opening of its latest Good Manufacturing Practice (GMP) facility in Singapore. The facility will support cell manufacturing for immunotherapies in Singapore and across the world, and create more than 200 jobs for the cell and gene therapy (CGT) industry in the next three to five years. [From Left to Right] Dr Han Deping, Chief Medical Officer, Biosyngen; Dr Cheong Wei Yang, Deputy Secretary (Technology), Ministry of Health; Ms Joan Zhang, Chairman, Biosyngen; Mr Alvin Tan, Minister of State for the Ministry of Trade & Industry; Ms Lily Peng Yuemei, Deputy Party Secretary, Director, Knowledge City (Guangzhou) Investment Group and Dr Michelle Chen, Chief Operating Officer, BiosyngenThe issuer is solely responsible for the content of this announcement.
About Biosyngen
With R&D powered by scientists from Singapore, China, Germany, Australia, France, and America, Biosyngen is dedicated to give cancer patients a second chance by developing first-in-class innovative immunotherapies. Aiming for the global market with dual R&D centers and GMP facilities set in Singapore and China, Biosyngen owns a product portfolio with potential global market of more than 50 billion USD. Biosyngen possesses exclusive licenses and patented therapies targeting multiple solid tumors and hematological malignancies including nasopharyngeal cancer, gastric cancer, lymphoma and posttransplant lymphoproliferative disorders. We collaborate closely with the world's leading biomedical research and clinical institutes including A*STAR, Helmholtz Zentrum München, Hannover Medical School, Sun Yat-Sen University Cancer Center to advance our R&D process and conduct clinical trials in Singapore, Australia and China. Utilizing our strong R&D capability and translational medicine platform, we have been able to engage the end-to-end cycle of drug development including lead identification, preclinical studies cell production and quality control, regulatory filing and clinical studies, thus integrating R&D, manufacturing and commercialization
Source https://www.media-outreach.com/news/singapore/2023/06/28/229371/